ACMG Releases Policy Statement on Genomic Sequencing
News Mar 30, 2012
These new guidelines should help guide clinicians as they use such testing and address:
The categories of patients and types of clinical situations for which such testing will likely be the most helpful
What patients need to know about genomic sequencing before it is performed
Principles that guide the use of information from genomic sequencing to improve patient care and medical decision-making
ACMG President Wayne Grody, M.D., Ph.D., FACMG said upon the Statement's release, "The transition from traditional targeted gene testing to genome-wide analysis constitutes a genuine sea change in medicine, offering vastly enhanced diagnostic power along with unprecedented challenges in test interpretation and reporting. This policy represents the first professional guidance for appropriate integration of this new technology into clinical practice."
"Genomic sequencing is now transitioning from the research laboratory into the clinic and will have a transformative effect on healthcare," said Bruce R. Korf, M.D., Ph.D., FACMG, one of the authors of the new Policy Statement and past-president of the ACMG. "This statement by the American College of Medical Genetics and Genomics will help set the context for clinical genomic sequencing to insure maximum value and quality or our patients and the public."
In defining the need for this document, ACMG said in the Policy Statement, "Major advances in DNA sequencing technology have made it possible to do large-scale sequencing, up to and including whole genome sequencing, in an effort to identify a gene mutation that may provide a diagnosis for a patient with an abnormal phenotype. This strategy offers potential advantages over classic approaches in which genes are analyzed individually, often over a long period of time and at substantial expense. As a result, there is considerable interest in offering genomic sequencing-based tests on a clinical basis. This document outlines points to consider in the clinical application of genomic sequencing to the detection of germ-line mutations. It is expected that this document will require revision as this rapidly changing field evolves."
One of the main conclusions/recommendations of the Policy Statement is that genomic sequencing data must be integrated in the context of the medical and family history of the individual patient to guide medical decision-making. This should be done by a health provider who is familiar with the enormously complex and voluminous data that is obtained from genomic sequencing.
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018